摘要
Abstract
Objective To explore the relationship of IL-6,IL-6R and MCL1 with the prognosis of multiple myeloma(MM)by detecting the expression of serum IL-6,IL-6R,MCL1 and the bone metabolic markers(N-MID,PINP,β-CTX)in the patients with multiple myeloma(MM).Methods The patients with MM in this hospital were included into the MM group,and divided into three subgroups according to the clinical stages:stageⅠ,Ⅱ and Ⅲ groups,and contemporaneous subjects undergoing the physical examination served as the the control group,40 cases in each group.The expression levels of serum IL-6,IL-6R,MCL1,N-MID,PINP and β-CTX were detected by using the electrochemical luminescence immunoassay(ECILA).Results The lev-els of serum IL-6,IL-6R and MCL1 in the MM group were significantly higher than those in the control group (P<0.05),in which the stage Ⅲ subgroup was significantly higher than the stage Ⅱsubgroup(P<0.05),and the stage Ⅱsubgroup was significantly higher than the stage Ⅰsubgroup(P<0.05).The levels of serum N-MID and PINP in the MM group were significantly lower than those in the control group,in which the stageⅢ subgroup was significantly lower than the stage Ⅱ subgroup(P<0.05)and stage Ⅱ subgroup was lower than the stage Ⅰ subgroup(P<0.05).The level of serum β-CTX in the MM group was significantly higher than that in the control group(P< 0.05),in which the stage Ⅲ subgroup was significantly higher than the stage Ⅱsubgroup and the stage Ⅱsubgroup was significantly higher than the stage Ⅰsubgroup(P<0.05). The expression levels of serum IL-6,IL-6R and MCL1 were positively correlated with the clinical stages of MM(r=0.68,0.56,0.72,P<0.05).Conclusion The levels of serum IL-6,IL-6R and MCL1 in MM patients are significantly increased and positively correlated with the clinical stages of MM,which can be used for the e-valuation of bone injury and prognosis of M M.关键词
白细胞介素-6/白细胞介素-6受体/髓样细胞白血病蛋白1/多发性骨髓瘤/预后Key words
IL-6/IL-6R/MCL1/multiple myeloma/prognosis分类
医药卫生
